

# Physical activity during cancer treatment (PACT) study

<b>Submission date</b> 17/12/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 26/01/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 17/07/2020	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Petra Peeters

**Contact details**  
Universitair Medisch Centrum Utrecht  
Julius Center  
PO Box 85500  
Utrecht  
Netherlands  
3508 GA  
-  
p.h.m.peeters@umcutrecht.nl

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
NTR2138

# Study information

## Scientific Title

A randomised clinical trial of physical exercise during cancer treatment: the PACT study

## Acronym

PACT

## Study objectives

We hypothesise that early physical exercise by reducing complaints of fatigue will lead to a reduction in sick leave and production losses. Altogether, we expect that physical exercise during cancer treatment will be cost-effective.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Medical Ethics Committee of the University Medical Centre Utrecht, 27/02/2008, ref: 07/271/O

## Study design

Multicentre pragmatic randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Quality of life

## Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

## Health condition(s) or problem(s) studied

Breast cancer/colon cancer

## Interventions

During an intake, patients will be included, baseline measurements will be taken and patients will be randomly allocated to the intervention or control group. Participants assigned to the intervention group will receive usual care in combination with an 18-week supervised group exercise program. They will be encouraged to attend the exercise program two times a week supervised by a physiotherapist.

Participants who will be assigned to the control group will receive usual care, i.e., no exercise intervention.

We will assess the short term as well as the long term effects. Short-term effects will be measured 18 weeks after inclusion (at the end of the program) and long term effects will be measured 9 months after inclusion.

**Intervention Type**

Behavioural

**Primary outcome measure**

Measured at baseline, 18 weeks and 9 months:

1. Fatigue
2. Health service utilisation and sick leave

**Secondary outcome measures**

Measured at baseline, 18 weeks and 9 months:

1. Health related quality of life
2. Anxiety and depression
3. Physical fitness
4. Body composition
5. Cognitive behavioural aspects
6. Physical activity level

**Overall study start date**

01/01/2010

**Completion date**

31/12/2012

**Eligibility****Key inclusion criteria**

1. Recently diagnosed with breast or colon cancer (stage M0): histological diagnosis of cancer less than six (breast cancer) or ten (colon cancer) weeks ago
2. Treated with chemotherapy
3. Aged 25 - 75 years, either sex
4. Able to read and understand the Dutch language
5. Karnovsky Performance Status of 60 or higher
6. Able to walk 100 metres or more

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

300

**Total final enrolment**

92

**Key exclusion criteria**

1. Treated for cancer in the past five years (except basal skin cancer)
2. Contraindications for physical activity (Revised Physical Activity Readiness Questionnaire)

**Date of first enrolment**

01/01/2010

**Date of final enrolment**

31/12/2012

**Locations****Countries of recruitment**

Netherlands

**Study participating centre**

Universitair Medisch Centrum Utrecht

Utrecht

Netherlands

3508 GA

**Sponsor information****Organisation**

The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

**Sponsor details**

Laan van Nieuw Oost Indië 334

Den Haag

Netherlands

2593 CE

-

roossum@zonmw.nl

**Sponsor type**

Research organisation

**Website**

<http://www.zonmw.nl/>

**ROR**

<https://ror.org/01yaj9a77>

# Funder(s)

## Funder type

Research organisation

## Funder Name

Netherlands Organisation for Health Research and Development

## Alternative Name(s)

Netherlands Organisation for Health Research and Development

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

Netherlands

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	09/06/2010		Yes	No
<a href="#">Results article</a>	results	08/06/2015		Yes	No
<a href="#">Results article</a>	results	01/05/2016		Yes	No
<a href="#">Results article</a>	results	08/05/2019	10/01/2020	Yes	No
<a href="#">Results article</a>	follow up results	16/04/2020	17/07/2020	Yes	No